75 related articles for article (PubMed ID: 35767923)
61. Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis.
La Salvia A; Rossi A; Galetta D; Gobbini E; De Luca E; Novello S; Di Maio M
Clin Lung Cancer; 2017 Jan; 18(1):23-33.e1. PubMed ID: 27876230
[TBL] [Abstract][Full Text] [Related]
62. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
Rossi A; Chiodini P; Sun JM; O'Brien ME; von Plessen C; Barata F; Park K; Popat S; Bergman B; Parente B; Gallo C; Gridelli C; Perrone F; Di Maio M
Lancet Oncol; 2014 Oct; 15(11):1254-62. PubMed ID: 25232001
[TBL] [Abstract][Full Text] [Related]
63. Endpoint surrogacy in oncological randomized controlled trials with immunotherapies: a systematic review of trial-level and arm-level meta-analyses.
Zhang J; Liang W; Liang H; Wang X; He J
Ann Transl Med; 2019 Jun; 7(11):244. PubMed ID: 31317014
[TBL] [Abstract][Full Text] [Related]
64. A meta-analysis: Evaluation of safety and efficacy of the epidermal growth factor receptor-tyrosine kinase inhibitor monotherapy versus platinum-based doublets chemotherapy in East Asia.
Zhang XF; De-Sheng LV; Li M; Sun GE; Liu CH
Indian J Cancer; 2017; 54(1):104-114. PubMed ID: 29199672
[TBL] [Abstract][Full Text] [Related]
65. Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis.
Veas Rodríguez J; Prieto A; Vilaprinyo E; Bonet M; Diez M; Salud A; Montal R
Crit Rev Oncol Hematol; 2024 Jun; 201():104416. PubMed ID: 38871262
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
[TBL] [Abstract][Full Text] [Related]
67. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.
Yang S; Zhan J; Xu X
Endocrine; 2023 Dec; 82(3):491-497. PubMed ID: 37702900
[TBL] [Abstract][Full Text] [Related]
68. Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Ostoros G; Hettle R; Georgoulia N; Berktas M; Chander P; Diaz Perez I; Couto AM; Eichinger C; Field P; Morten P
Expert Rev Anticancer Ther; 2023; 23(12):1305-1313. PubMed ID: 37850939
[TBL] [Abstract][Full Text] [Related]
69. The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints.
Giuffrida P; Celsa C; Antonucci M; Peri M; Grassini MV; Rancatore G; Giacchetto CM; Cannella R; Incorvaia L; Corsini LR; Morana P; La Mantia C; Badalamenti G; Brancatelli G; Cammà C; Cabibbo G
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359347
[TBL] [Abstract][Full Text] [Related]
70. Research in interventional oncology: How sound is the evidence base?
Kaufmann NC; Zeka B; Pereira PL
J Med Imaging Radiat Oncol; 2023 Dec; 67(8):903-914. PubMed ID: 37170844
[TBL] [Abstract][Full Text] [Related]
71. Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis.
Goring S; Varol N; Waser N; Popoff E; Lozano-Ortega G; Lee A; Yuan Y; Eccles L; Tran P; Penrod JR
Lung Cancer; 2022 Aug; 170():122-132. PubMed ID: 35767923
[TBL] [Abstract][Full Text] [Related]
72. Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis.
Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Tilki D; Shariat SF; Gallucci M; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
Crit Rev Oncol Hematol; 2022 Jan; 169():103534. PubMed ID: 34823022
[TBL] [Abstract][Full Text] [Related]
73. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
74. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
75. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]